Explore the current challenges in the biotech sector and discover resilient companies like Amgen, Gilead, Moderna, Illumina, and Vertex that present promising investment opportunities.
Explore Illumina, Inc.'s 8-K report filed on March 10, 2025, detailing significant corporate events. Key stock info and SEC details included.
Explore Illumina, Inc.'s March 25, 2025, 8-K report detailing significant corporate changes and stock information. Essential for investors and analysts monitoring regulatory compliance.
Explore Illumina, Inc.'s latest 8-K filing report detailing important updates and regulatory information effective March 24, 2025. Stay informed on ILMN's corporate developments!
Explore Illumina, Inc.'s Q4 2024 financial results, revealing $3.99B revenue, $1.22B net loss, and GRAIL segment challenges. Key insights and future outlook provided.
Explore Illumina, Inc.'s 8-K/A filing detailing amendments, future reporting dates, and SEC compliance. Stay informed about stock updates and corporate transparency.
Explore Illumina, Inc.'s 8-K filing dated January 14, 2025, detailing important corporate events. Access essential stock info and SEC compliance in this concise report.